XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are intolerant to standard therapies. XNW27011 is an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), a transmembrane protein important to tight junctions. The study consists of 2 parts: Part 1 is the dose-escalation phase (Phase I), and Part 2 is the does-expansion phase (Phase II). In phase I part of the study, approximately 42 patients with locally advanced an

Trial Details

NCT ID
NCT06792435
Phase
PHASE1 / PHASE2
Sponsor
Evopoint Biosciences Inc.
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • XNW27011
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Phase I (Dose Escalation)：
  • Patients are willing and able to provide written informed consent or where consent is provided by legally authorized representatives.
  • Age ≥18 years old when signing the informed consent form.
  • Patients with a histologically or cytologically-confirmed, locally advanced or metastatic solid tumor, which has failed on standard therapy or is i…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →